Plasma cell surface antigens (N/A)

Plasma cell surface antigens are a diverse group of proteins expressed on the membrane of terminally differentiated B-cells, serving as primary therapeutic targets for plasma cell dyscrasias such as multiple myeloma [PMID: 30254373]. Key antigens in this category include CD38, B-cell maturation antigen (BCMA), SLAMF7, and CD138, each playing distinct roles in cell signaling, bone marrow niche adhesion, and survival [PMID: 30048762, 31859245]. Therapeutic interventions targeting these molecules include monoclonal antibodies like daratumumab, antibody-drug conjugates, and T-cell engaging therapies such as CAR-T cells and bispecific antibodies [PMID: 26035255, 35661166]. These treatments aim to selectively deplete malignant plasma cells while minimizing damage to other hematopoietic lineages. However, the clinical use of these targets is often complicated by systemic immune suppression, cytokine release syndrome, and the potential for antigen escape [PMID: 31859245]. Understanding the density and distribution of these antigens is crucial for optimizing patient selection and monitoring treatment efficacy. These antigens are also used as diagnostic markers to identify and quantify plasma cell populations in bone marrow aspirates.

Other names

Plasma cell markersMultiple myeloma surface antigensB-cell differentiation antigensPlasma cell membrane proteins

Drugs targeting these antigens utilize various mechanisms including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. Advanced modalities like bispecific antibodies and CAR-T cells redirect T-cell cytotoxicity specifically toward cells expressing these surface markers [PMID: 30254373, 35661166].